Aktis Oncology, Inc. Common stock (AKTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has a cash flow conversion efficiency ratio of 0.146x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($-87.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aktis Oncology, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Aktis Oncology, Inc. Common stock carry for a breakdown of total debt and financial obligations.
Aktis Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Swedish Logistic Property AB Series B
ST:SLP-B
|
0.020x |
|
Dongguan Kingsun Optoelectronic Co Ltd
SHE:002638
|
-0.001x |
|
Uroica Mining Safety Eng
SHE:300099
|
0.002x |
|
MFA Financial Inc
NYSE:MFA
|
0.008x |
|
Northern Dynasty Minerals Ltd
TO:NDM
|
-0.089x |
|
Hubei Heyuan Gas Co Ltd
SHE:002971
|
0.087x |
|
Xiamen International Airport Co Ltd
SHG:600897
|
0.043x |
|
Certara Inc
NASDAQ:CERT
|
0.027x |
Annual Cash Flow Conversion Efficiency for Aktis Oncology, Inc. Common stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Aktis Oncology, Inc. Common stock from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Aktis Oncology, Inc. Common stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-87.80 Million | $14.76 Million | -0.168x | -123.79% |
| 2024-06-30 | $-57.09 Million | $-40.35 Million | 0.707x | +9.06% |
| 2023-12-31 | $-46.31 Million | $-30.00 Million | 0.648x | +224.67% |
| 2023-06-30 | $86.24 Million | $-44.82 Million | -0.520x | -155.14% |
| 2022-12-31 | $-19.23 Million | $-18.12 Million | 0.943x | +315.70% |
| 2022-06-30 | $103.43 Million | $-45.20 Million | -0.437x | 0.00% |
| 2021-12-31 | $103.43 Million | $-45.20 Million | -0.437x | -74.72% |
| 2021-06-30 | $117.41 Million | $-29.36 Million | -0.250x | +51.29% |
| 2020-12-31 | $41.49 Million | $-21.30 Million | -0.513x | 0.00% |
| 2020-06-30 | $41.49 Million | $-21.30 Million | -0.513x | +24.57% |
| 2019-12-31 | $25.95 Million | $-17.67 Million | -0.681x | 0.00% |
| 2019-06-30 | $25.95 Million | $-17.67 Million | -0.681x | +33.61% |
| 2018-12-31 | $13.85 Million | $-14.20 Million | -1.025x | 0.00% |
| 2018-06-30 | $13.85 Million | $-14.20 Million | -1.025x | -177.37% |
| 2017-12-31 | $15.01 Million | $-5.55 Million | -0.370x | 0.00% |
| 2017-06-30 | $15.01 Million | $-5.55 Million | -0.370x | +10.09% |
| 2016-06-30 | $2.68 Million | $-1.10 Million | -0.411x | 0.00% |
| 2015-12-31 | $2.68 Million | $-1.10 Million | -0.411x | -75.57% |
| 2015-06-30 | $4.19 Million | $-980.04K | -0.234x | 0.00% |
| 2014-12-31 | $4.19 Million | $-980.04K | -0.234x | +92.00% |
| 2014-06-30 | $9.21K | $-26.98K | -2.928x | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more